Diversity Action Plans in Clinical Trials

This Viewpoint discusses the US Food and Drug Administration’s upcoming mandate on diversity actions plans for trial sponsors and the importance of developing accountability mechanisms to monitor those plans.

Authors

Rebecca Metcalfe (ORCID: https://orcid.org/0000-0001-5583-5679)
Jay Park (ORCID: https://orcid.org/0000-0001-5454-014X)

Institutions

University of British Columbia (CA)
Impact (CA)
McMaster University (CA)

Publication Details

Journal: JAMA
Published: 2024-09-20
DOI: https://doi.org/10.1001/jama.2024.16009
Citations: 4
Primary Topic: Ethics in Clinical Research
Type: article
Field-Weighted Citation Impact: 2.17

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Diversity Action Plans in Clinical Trials

Rebecca Metcalfe, Jay Park

Sep 20, 2024

4 citations

JAMA

Ethics in Clinical Research

2.17

article

Diversity Action Plans in Clinical Trials

Rebecca Metcalfe, Jay Park

September 20, 2024article en

4 citations

Abstract

JAMAVol. 332(21)

University of British Columbia (CA), Impact (CA), McMaster University (CA)

Partnerships for the goals

Openalex Percentile: Top 12%

Ethics in Clinical Research

2.17

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Diversity Action Plans in Clinical Trials — Rebecca Metcalfe, Jay Park · JAMA (2024) | TGRS Research Map | TGRS